Skip to main content
    Z

    Zenas BioPharma, Inc. Common Stock (ZBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.93
    -0.08 (-0.29%)

    Market Cap: $1.90B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Zenas BioPharma, Inc. Common Stock (ZBIO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Zenas BioPharma, Inc. Common Stock reported revenue of $10.00M for the fiscal year ended Dec 31, 2025, up 100.0% from the year before. That year, net income was -$377.74M with a net margin of -3777.4%, operating cash flow was -$172.33M and free cash flow was -$172.35M. The quarter ended Sep 30, 2026 had revenue of $10.00M and net income of -$108.92M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$10.00M+100.0%100.0%-3830.6%-3777.4%
    Dec 2024$5.00M-90.0%100.0%-3277.8%-3139.8%
    Dec 2023$50.00MN/A100.0%-74.3%-74.2%
    Dec 2022$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2022 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Revenue$10.00M$5.00M$50.00M$0
    Cost of revenue$0$0$0$61.69M
    Gross profit$10.00M$5.00M$50.00M-$61.69M
    Research and development$339.74M$139.14M$70.03M$62.69M
    Operating income-$383.06M-$163.89M-$37.15M-$76.20M
    Net income-$377.74M-$156.99M-$37.12M-$119.28M
    EBITDAN/AN/A-$36.71M-$75.12M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$10.00M$1.00M$0$10.00M$0$0$10.00M$5.00M$0$0$0$0
    Gross profit$10.00M$1.00M$0-$10.00K$0$0$10.00M$5.00M$0$0$0-$20.42M
    Operating income-$103.41M-$107.66M-$77.35M-$237.98M-$52.58M-$55.16M-$37.33M-$55.62M-$40.98M-$39.70M-$27.58M-$24.78M
    Net income-$108.92M-$111.46M-$80.99M-$240.44M-$51.50M-$52.22M-$33.57M-$52.60M-$38.61M-$37.98M-$27.80M-$24.59M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $1.11M by $109.53M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Total assets$383.64M$369.97M$68.18M$74.58M
    Current assets$351.17M$355.92M$59.80M$68.44M
    Cash and equivalents$110.64M$319.74M$56.86M$67.21M
    Total liabilities$141.50M$57.51M$43.81M$266.87M
    Short-term debt$1.11M$785.00K$556.00K$715.00K
    Long-term debt$0$0$20.30MN/A
    Shareholder equity$242.14M$312.46M-$225.72M-$192.29M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$675.22M$701.69M$747.68M$383.64M$322.02M$293.08M$333.77M$369.97M$403.43M$199.95M$49.05M$68.18M
    Total liabilities$462.91M$454.59M$411.85M$141.50M$125.59M$53.46M$49.45M$57.51M$44.00M$39.12M$301.55M$293.90M
    Cash and equivalents$177.78M$196.58M$500.22M$110.64M$115.56M$44.01M$196.55M$319.74M$360.04M$183.93M$37.15M$56.86M
    Shareholder equity$212.31M$247.10M$335.83M$242.14M$196.43M$239.63M$284.32M$312.46M$359.44M$160.83M-$252.50M-$225.72M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Operating cash flow-$172.33M-$119.67M-$30.53M-$65.65M
    Capital expenditures$18.00K$131.00K$17.00K$2.20M
    Free cash flow-$172.35M-$119.81M-$30.55M-$67.85M
    Share repurchases$12.66M$6.33M$0N/A
    Investing cash flow-$251.89M-$30.55M-$17.00K-$2.20M
    Financing cash flow$215.28M$412.96M$20.12M$59.39M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$57.98M-$57.24M-$75.20M-$52.41M-$41.13M-$41.74M-$37.05M-$38.55M-$31.06M-$30.96M-$19.10M-$15.40M
    Capital expenditures$1.00KN/A$2.00K$30.00M$5.00M$0$18.00K$74.00K$0$35.00K$22.00K$17.00K
    Free cash flow-$57.98MN/A-$75.20M-$82.41M-$46.13M-$41.74M-$37.07M-$38.63M-$31.06M-$30.99M-$19.12M-$15.42M
    Last 12 quarters

    Frequently Asked Questions About ZBIO

    What is Zenas BioPharma, Inc. Common Stock's annual revenue?

    Zenas BioPharma, Inc. Common Stock reported revenue of $10.00M for the fiscal year ended Dec 31, 2025.

    How fast is Zenas BioPharma, Inc. Common Stock's revenue growing?

    Revenue was up 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Zenas BioPharma, Inc. Common Stock profitable?

    No. Zenas BioPharma, Inc. Common Stock reported net income of -$377.74M for the fiscal year ended Dec 31, 2025, with a net margin of -3777.4%.

    How much free cash flow does ZBIO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$172.33M minus capital expenditures of $18.00K produced free cash flow of -$172.35M.

    How much debt does Zenas BioPharma, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $1.11M and cash and equivalents of $110.64M.